Latest Revenue Guidance News

Acusensus Limited reported a robust FY25 with 20% revenue growth and a significant 84% jump in total contract value, setting the stage for an ambitious FY26 forecast of up to 41% revenue increase.

Infomedia Ltd reported solid FY25 financial results with a 7% rise in underlying cash EBITDA and announced a lucrative take-private offer from TPG Capital at a 41% premium. The company’s strategic AI investments and contract renewals underpin its growth trajectory.

Infomedia Ltd reported a solid FY25 with revenue up 4% and NPAT soaring 32%, while advancing AI initiatives and securing a takeover offer from TPG Capital.

Helia Group reports a robust 38% rise in statutory net profit for the first half of 2025, alongside a special dividend declaration, while navigating looming challenges from government policy shifts and lender contract changes.

Cogstate Limited has reported a landmark FY25 with revenue up 22% and net profit before tax nearly doubling, driven by a surge in clinical trials contracts and strategic innovation. The company also declared its maiden fully franked dividend and outlined ambitious growth plans including AI product launches and an expanding Medidata partnership.

NRW Holdings delivered a robust FY25 performance, posting a 12.2% revenue increase to $3.27 billion and securing a strong $6.1 billion order book. The company’s FY26 outlook remains positive with expected revenue growth and improved earnings.

Megaport Limited delivered a robust FY25 with 20% growth in annual recurring revenue and EBITDA surpassing guidance, setting the stage for continued expansion in FY26.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.

Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial expansion and strategic investments in R&D and manufacturing. The company confirms full-year guidance while advancing key clinical trials and product launches.

Fisher & Paykel Healthcare has issued strong first half FY26 guidance, forecasting significant revenue and profit growth while navigating new US tariffs. Meanwhile, director Pip Greenwood announces her retirement after eight years on the board.

Vista Group International reports robust H1 2025 results with strong revenue growth and margin expansion, driven by accelerating client adoption of its Vista Cloud platform and a new Embedded Payments initiative.

Austin Engineering has restated its FY24 financials due to revenue recognition errors in its Chilean subsidiary, leading to an upward revision of its FY25 revenue and profit guidance.